Beckman Coulter Diagnostics
Beckman Coulter – SARS-CoV-2 Assays
Highlights:
The Access SARS-CoV-2 IgG (1st IS) assay and the Access SARS-CoV-2 IgM assay detect antibodies to the receptor-binding domain (RBD) of the spike protein which may be important to identify an immune response.
Adding SARS-CoV-2 IgG (1st IS) and / or IgM testing to assess COVID-19 patients provides greater clinical clarity for patient assessment.
- Access SARS-CoV-2 IgG (1st IS) assay
- The overall specificity of the Access SARS-CoV-2 IgG (1st IS) assay is 99.8 percent and the sensitivity ≥14 days post-symptom onset was 100 percent
- Access SARS-CoV-2 IgM assay
- The overall specificity of the Access SARS-CoV-2 IgM assay is 99.9 percent and the sensitivity >18 days post symptom onset and post positive PCR was 100 percent
